Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 3/20 | 0.55 |
| ▸ | DDT | P30046 | 3/20 | 0.54 |
| ▸ | DDX3X | O00571 | 5/20 | 0.53 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | APP | P05067 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3116253 | 0.85 | MIF (0.59) | MIFDDTMEN1KMT2ANAMPT | |
| SCHEMBL15355919 | 0.82 | MIF (0.58) | MIFDDT | |
| SCHEMBL3099909 | 0.75 | RIPK1 (0.46) | DDX3XSMN1; SMN2NPC1HPGDRAB9A | |
| SCHEMBL3107316 | 0.74 | ACKR3 (0.57) | MIFRAB9A | |
| SCHEMBL17978475 | 0.69 | DDX3X (1.00) | DDX3X | |
| SCHEMBL17978592 | 0.69 | DDX3X (1.00) | DDX3XMEN1KMT2A | |
| SCHEMBL22736963 | 0.68 | FOLH1 (0.60) | MIF | |
| SCHEMBL13480551 | 0.68 | KMT2A (0.62) | NPC1HPGDRAB9AMEN1KMT2A | |
| SCHEMBL31475190 | 0.68 | HDAC1 (0.62) | SMN1; SMN2NPC1HPGDRAB9AMEN1 | |
| SCHEMBL7217481 | 0.68 | HDAC1 (0.62) | SMN1; SMN2NPC1HPGDRAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7803822-B2 | Triazole derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-28 | — | — | US | disclosed |
| US-20090105253-A1 | Triazole Derivative and Use Thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-04-23 | — | — | US | disclosed |
| EP-1867331-A1 | TRIAZOLE DERIVATIVE AND THE USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2007-12-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105253-A1 | Triazole Derivative and Use Thereof | F2R, HRH4, F2RL3 | MIF 4297/4885DDT 4203/4885DDX3X 3591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.